Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;9(2):403-417.
doi: 10.1007/s40120-020-00214-3. Epub 2020 Oct 3.

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine

Ivan Urits  1 , Melis Yilmaz  2 , Karina Charipova  3 , Kyle Gress  3 , Ehab Bahrum  3 , Michael Swett  3 , Amnon A Berger  4 , Hisham Kassem  5 , Anh L Ngo  2   6 , Elyse M Cornett  7 , Alan D Kaye  8 , Omar Viswanath  8   9   10   11
Affiliations
Review

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine

Ivan Urits et al. Neurol Ther. 2020 Dec.

Abstract

Purpose of review: This is a comprehensive review of the current literature on the usage of galcanezumab for migraine treatment. It reviews the biology, pathophysiology, epidemiology, diagnosis, and conventional treatment of migraines, then compares the literature available for galcanezumab with historical treatment options.

Recent findings: Migraine is a common headache disorder and constitutes a significant source of distress from both a personal and societal perspective. Conventional treatment includes abortive and preventive treatment. Treatment options are limited and may be only partially or minimally effective in some of the population. Recent evidence points to metabolic changes in the brain as possible causes of migraine, via reduced available energy or a spiking need for it, resulting in a relative insufficiency. This leads to trigeminocervical complex (TCC) activation and a headache episode, modulated by calcitonin gene-related peptide (CGRP). Galcanezumab (Emgality) is a monoclonal antibody targeting CGRP that is given in a monthly injection for the prevention of migraines. Its safety was previously shown in phase 1 and 2 trials, and recent phase 3 trials showed efficacy, with up to 50% reduction in monthly migraine days and improved functional capacity in migraineurs. Studies show that the drug is well tolerated and safe. Migraine headache is a common neurological syndrome that causes great pain and suffering. Treatment options today are limited. Galcanezumab does not prevent migraines, but it is effective in decreasing their frequency and length. It is also much better tolerated than the currently existing therapies. While it is unlikely to provide monotherapy for migraines, it is a novel therapy that may be added for cases of severe or frequent migraines.

Keywords: CGRP; Chronic pain; Galcanezumab; Headache; Migraine; Monoclonal antibody.

PubMed Disclaimer

References

    1. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631–649. - PubMed
    1. Lipton R, Bigal M, Diamond M, Freitag F, Reed M, Stewart W, AA Group Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343. - PubMed
    1. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache J Head Face Pain. 2018;58(4):496–505. - PubMed
    1. Ong JJY, Wei DYT, Goadsby PJ. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs. 2018;78(4):411–437. - PubMed
    1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. - PubMed